Te Ahumairangi Investment Management Ltd Invests $9.48 Million in DaVita Inc. $DVA

Te Ahumairangi Investment Management Ltd acquired a new stake in DaVita Inc. (NYSE:DVA) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 42,612 shares of the company’s stock, valued at approximately $9,480,000. DaVita makes up 1.5% of Te Ahumairangi Investment Management Ltd’s investment portfolio, making the stock its 17th largest position. Te Ahumairangi Investment Management Ltd owned about 0.07% of DaVita as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of DVA. BlackRock Inc. purchased a new position in shares of DaVita in the second quarter valued at $547,520,000. Arrowstreet Capital Limited Partnership grew its stake in DaVita by 114.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after acquiring an additional 636,191 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in DaVita during the 2nd quarter valued at about $101,127,000. Norges Bank acquired a new position in DaVita during the fourth quarter worth about $49,164,000. Finally, Corient Private Wealth LLC lifted its holdings in shares of DaVita by 1,493.1% in the fourth quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after purchasing an additional 335,809 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Price Performance

Shares of NYSE:DVA opened at $174.21 on Monday. The firm has a market capitalization of $11.11 billion, a PE ratio of 14.26, a P/E/G ratio of 0.58 and a beta of 0.88. The business has a 50-day moving average of $214.96 and a two-hundred day moving average of $182.03. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $247.49.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, research analysts anticipate that DaVita Inc. will post 14.57 earnings per share for the current year.

Wall Street Analyst Weigh In

DVA has been the topic of a number of recent research reports. TD Cowen upgraded shares of DaVita from a “hold” rating to a “buy” rating and upped their target price for the company from $201.00 to $220.00 in a report on Friday, August 7th. Barclays boosted their price objective on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. Raymond James Financial set a $220.00 price objective on DaVita in a research report on Friday, August 7th. Finally, Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, DaVita has an average rating of “Hold” and an average target price of $221.75.

Insider Buying and Selling

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.90% of the stock is currently owned by company insiders.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.